Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
about
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancyAcute lymphoblastic leukaemiaTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicineCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemia: Integrating genomics into therapyPrognostification of ALL by CytogeneticsLNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitorsCo-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunctionPerspectives on the causes of childhood leukemiaGermline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.ETV6 in hematopoiesis and leukemia predisposition.Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subsetIdentification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analysesDoes TP53 guard ALL genomes?The molecular regulation of Janus kinase (JAK) activationMutational analysis of primary central nervous system lymphoma.Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemiaThe origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemiaA recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis.Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibitionEvaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Identification of differentially expressed genes associated with prognosis of B acute lymphoblastic leukemia.Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemiaGenome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line.Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.Improving access to novel agents for childhood leukemia.PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug developmentKRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
P2860
Q24314163-5BBCF590-E106-43C2-B289-1828842AB8FAQ24602387-22120372-43EE-45F1-8740-237061793EA5Q26829652-99D63F70-4A19-4D14-8C57-9C043EE151BAQ26864460-09A5FB98-F521-45CD-8029-AF0C499A803FQ27025242-8054073B-55CF-4614-9FB7-6F42BEB9EF06Q28080463-8B2DE4CA-7E20-4C41-87E3-7A91B4D33BF8Q28087446-43556F44-B2B6-46A2-85C5-9125C0F2CC90Q28274115-0388AE09-2B15-4D95-9081-147953369D70Q28276513-978FF417-8A8F-4863-8EA1-E7D9349B2D93Q28391712-DD0DDC02-5C44-4533-A929-4496B87925B8Q33423823-3397C8BB-FF17-4E48-9CFD-3FF9A758974CQ33442887-8DCCB0F1-047E-48A1-940A-8F4CDC9331C2Q33573735-A193873A-FF64-4F43-8B8B-BC5C7BE57B16Q33622342-35059160-15C4-48F9-96E1-65B1931F2EEEQ33694514-364C7C48-B0BC-42B4-AF8B-6100B5DD6339Q33705933-86959744-640A-4FB5-AEF2-D328BE0947E2Q33711119-DC8FC2C6-D426-4F61-A1DD-5541AB02F772Q33728277-80E9BE74-A654-48EF-A496-70E527D22523Q33798544-88CF7A40-6D0E-4EB8-BA34-992EA08B31DCQ33857008-BF49EE93-D9B9-446C-AA14-104B58A0EC61Q33886848-D83A181A-1926-4873-BF29-2B4A444917F6Q33956113-7D911B29-DF11-4F41-BA24-D6BA7A93611EQ34104139-0707AD0D-2ED6-4B72-8116-995C4211DF6AQ34106849-3BFD948D-722D-4B7C-AFE3-A282B4D770AEQ34167952-A4E13955-6BD1-47E2-8803-23595BC078F2Q34172033-771B6B6C-FC4E-4D30-9C02-7409912DD341Q34325522-490F67F8-8740-4509-92E3-70C5123A9A51Q34369388-31B9DFEA-6C4E-4CCE-B708-0407EF0EE5FBQ34571956-19C16DEC-8276-40BC-996F-8FB4981D8887Q34580110-A3A2E196-19DC-4F16-8122-5AA61C91678DQ35079398-5851B6B1-812B-4C85-983A-3AA9C55270AAQ35162503-52C38ABF-6F52-497E-B501-6DFEAC23B5DFQ35227439-613050E7-ACCF-478E-B231-7737FDF2B8A4Q35500533-5826100E-6B07-4980-8C91-F52B36817C27Q35576105-A3DAFD37-028E-4C3F-8210-B2515887BF7DQ35663219-A66BD857-BB4B-482B-8589-6FAD9B57F620Q35688742-436D8BAA-5016-4AC8-BCB1-99434737EB5CQ35692410-20655352-C742-45D7-9E99-06FCBD799B78Q35838562-50FCB862-FBB6-4BD0-8AF0-CD54FA3C528CQ35932148-BD2C1724-870B-4681-B0A6-3374F8B7495A
P2860
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Key pathways are frequently mu ...... the Children's Oncology Group.
@ast
Key pathways are frequently mu ...... the Children's Oncology Group.
@en
type
label
Key pathways are frequently mu ...... the Children's Oncology Group.
@ast
Key pathways are frequently mu ...... the Children's Oncology Group.
@en
prefLabel
Key pathways are frequently mu ...... the Children's Oncology Group.
@ast
Key pathways are frequently mu ...... the Children's Oncology Group.
@en
P2093
P2860
P50
P1433
P1476
Key pathways are frequently mu ...... the Children's Oncology Group.
@en
P2093
Bruce M Camitta
Cheryl L Willman
Daniela S Gerhard
Gregory H Reaman
I-Ming Chen
James R Downing
Jinghui Zhang
Kenneth H Buetow
Malcolm A Smith
P2860
P304
P356
10.1182/BLOOD-2011-03-341412
P407
P577
2011-06-16T00:00:00Z